scholarly journals Sexual Dysfunction in Patients With Urinary Bladder Stones but no Bladder Outlet Obstruction

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhi-Cheng Gong ◽  
Zhi-Liang Wu ◽  
Yao-An Wen ◽  
Jie-Peng Zou ◽  
Xisheng Wang ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Sexual Dysfunction ◽  
Urinary Bladder ◽  
Sexual Function ◽  
Repeated Measures ◽  
Bladder Stone ◽  
Surgical Removal ◽  
Bladder Stones ◽  
Male Patients ◽  
Primary Bladder

Objective: To explore the correlates of sexual dysfunction and lower urinary tract symptoms (LUTS) in male patients with urinary bladder stones and to determine the effect of stone extraction on recovery of sexual function.Materials and Methods: A total of 87 male patients with primary bladder stones were studied from January 2015 to May 2016. All patients underwent pneumatic lithotripsy for bladder stones. Sexual dysfunction was assessed based on sexual function assessment scales. The relationship of bladder stones with sexual dysfunction or LUTS was assessed using a two-sample t-test. Postoperative improvement of sexual function was assessed by repeated measures Analysis of Variance (ANOVA).Results: Forty-one patients had primary bladder stones and 46 had secondary stones from the kidneys. Eighty-three of 87 patients (95%) had sexual dysfunction; 79 patients (91%) had both sexual dysfunction and LUTS. There was a significant association between bladder stones and sexual dysfunction, between sexual dysfunction and LUTS, and between bladder stone and LUTS (p < 0.05). There was no significant association between the course of illness, size and number of bladder stones, or urinary tract infection with sexual function (p > 0.05). In addition, among 83 patients with both bladder stone and sexual dysfunction, 61 patients (73%) had benign prostatic hyperplasia (BPH) and 22 patients (27%) had no BPH. On postoperative evaluation at 3 months, sexual dysfunction scores were significantly improved in 77 patients (88.5%)Conclusion: Patients with bladder stones have a high incidence of sexual dysfunction, particularly those with co-existing LUTS and BPH. About 1/3 patients without BPH had sexual dysfunction and surgical removal of bladder stones significantly improved sexual function and LUTS.

scholarly journals Giant Urinary Bladder Stone in a Middle-Aged Male

EMJ Urology ◽  
2022 ◽  
Author(s):  
João Cleber Coutinho Pires ◽  
Breno Bittencourt de Brito ◽  
Fabrício Freire de Melo ◽  
Cláudio Lima Souza ◽  
Márcio Vasconcelos Oliveira
Keyword(s):  
Urinary Tract ◽  
Urinary Bladder ◽  
Therapeutic Approach ◽  
Laboratory Tests ◽  
Accurate Diagnosis ◽  
Bladder Stone ◽  
Middle Aged ◽  
Bladder Stones ◽  
Life Threatening ◽  
Middle Aged Male

Urolithiasis is a disorder that affects 10–15% of people at least once in their lives. Among the calculi affecting the urinary tract are the bladder stones. Giant urinary bladder stones are rare and can potentially lead to the onset of intense symptoms as well as life threatening repercussions. This disorder demands an accurate diagnosis with the use of imaging tools and laboratory tests, as well as an agile and appropriate therapeutic approach in order to prevent unfavourable outcomes. This paper reports on a bladder stone that was 18.5 cm in diameter and weighed 1.328 kg, which was extracted from a middle-aged male.

Obstructive uropathy from a giant urinary bladder stone: a rare urological emergency

2021 ◽  
Vol 14 (1) ◽  
pp. e234339
Author(s):  
Subhabrata Mukherjee ◽  
Rajan Kumar Sinha ◽  
Mussab Hamdoon ◽  
Jai Abbaraju
Keyword(s):  
Urinary Tract ◽  
Urinary Bladder ◽  
Obstructive Uropathy ◽  
Outlet Obstruction ◽  
Emergency Admission ◽  
Urethral Catheter ◽  
Bladder Stone ◽  
Urinary Flow ◽  
Ultrasound Scan ◽  
Tract Infections

A 53-year-old man presented with lower urinary tract symptoms and recurrent urinary tract infections since last 3 years without being investigated or treated properly. Examination revealed a hard mobile lump in the pelvis, and blood investigations showed raised serum creatinine of 2.9 mg/dL. Subsequent urgent ultrasound scan showed a large urinary bladder stone with bilateral hydroureteronephrosis, and X-ray kidney, ureter and bladder demonstrated a 9 cm×6 cm elliptical radio-opaque shadow in the pelvis. He underwent emergency admission followed by open cystolithotomy on the next day. He was discharged after 48 hours with a urethral catheter. After 2 weeks, his renal function recovered completely; repeat ultrasound scan revealed complete resolution of hydronephrosis. Urethral catheter was removed following a normal cystogram. Uroflowmetry after 6 weeks revealed underlying bladder outlet obstruction, and he was started on alpha blocker which improved his urinary flow.

scholarly journals Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression?

2005 ◽  
Vol 185 (2) ◽  
pp. 345-352 ◽  
Author(s):  
M R Kraus ◽  
A Schäfer ◽  
T Bentink ◽  
M Scheurlen ◽  
B Weissbrich ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Rating Scale ◽  
Sex Hormone ◽  
Total Testosterone ◽  
Male Patients

Decrease of libido and erectile dysfunction are reported by male patients during antiviral therapy of chronic hepatitis C, but therapy-associated underlying factors for sexual dysfunction are not well defined. To assess putative contributions of interferon-induced sex hormone changes to sexual dysfunction, we prospectively investigated changes in free testosterone, total testosterone, dehydroepiandrosterone sulfate, prolactin, sex hormone-binding globulin, FSH and LH levels and psychometric self-assessment scores in 34 male patients treated with interferon alfa-2b (5 MIU three times weekly) (n=19)+ ribavirin (n=15) for 6–12 months. Depression was measured by the Hospital Anxiety and Depression Scale. Sexual dysfunction was evaluated by the Symptom Checklist 90 Item Revised and a five-point rating scale assessing sexual arousal disorder. Free and total testosterone decreased significantly during antiviral therapy in close correlation with libido/sexual function. Depression scores increased during therapy and were also significantly associated with sexual dysfunction. However, androgen levels displayed no significant correlation with depression. These results suggest that interferon-induced decrease in sexual function is associated – but not causally related –with both androgen reduction and increased depressive symptoms. These findings may affect care for male hepatitis C patients during interferon therapy.

Effectiveness of Relationship Enrichment program (REP) on sexual dysfunction and Satisfaction of Females with Multiple Sclerosis-An Educational Study

2021 ◽  
Vol 17 ◽  
Author(s):  
Negin Sayari ◽  
Katayon Vakilian ◽  
Zohre Khalajinia ◽  
Seyyed Amir Hejazi ◽  
Mostafa Vahedian
Keyword(s):  
Multiple Sclerosis ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Sexual Satisfaction ◽  
Repeated Measures ◽  
Intervention Group ◽  
Sexual Life ◽  
Educational Design ◽  
Significant Difference ◽  
Enrichment Program

Aims: Improving sexual function in women with disability such as multiple sclerosis was aimed. Background: Sexual dysfunction and the consequent low satisfaction is very common in females with Multiple Sclerosis (MS). Objectives: This study aimed to investigate the effectiveness of Relationship Enhancement Therapy (REP) on sexual function and satisfaction of females with MS. Methods: the present study was an educational design with two groups, in which 44 females with MS participated and their spouses (N= 88) participated and randomly divided in two groups of intervention (N= 22 couples) and control (N= 22 couples). They signed written consent forms and were included in the project. The intervention group received the REP in six 90-minute sessions. The groups completed standard questionnaires of sexual dysfunction and sexual satisfaction in three stages of pretest-posttest and 3 months later. The Descriptive and inferential statistics (Two- way repeated measures ANOVA, chi-square, t-test and Mann-Whitney U test) were used to analyze data. Results: The results of analysis showed that there was a clinically significant difference between the scores of sexual dysfunction in different phases of the assessment between two groups (p <0.05). Also sexual satisfaction was higher in the intervention group vs. in the control (p <0.05). Conclusion: according to the findings, marital enrichment program was effective in improvement of sexual function and sexual satisfaction of females with multiple sclerosis. It is recommended to healthcare providers to use enrichment alongside medical services to improve patients' sexual life.

Drug Dependence and Sexual Dysfunction: A Comparison of Intravenous Users of Narcotics and Oral Users of Amphetamines

1974 ◽  
Vol 124 (582) ◽  
pp. 431-434 ◽  
Author(s):  
M. R. Gossop ◽  
R. Stern ◽  
P. H. Connell
Keyword(s):  
Sexual Dysfunction ◽  
Sexual Function ◽  
Drug Dependence ◽  
Drug Effects ◽  
Specific Drug ◽  
Sexual Performance ◽  
Opiate Drugs ◽  
Male Patients ◽  
Drug Dependent ◽  
Specific Determinant

Diminished sexual activity among individuals dependent upon the opiate drugs (heroin, morphine, methadone, etc.) has been noted by Freedman (1967) and by Jurgensen (1966). A study of four populations of male patients (controls, abstainers, heroin addicts and patients maintained on methadone), suggested that although factors other than the specific drug effects may be important determinants of sexual difficulties, that the drug itself may act as a specific determinant (Cushman, 1972). This was supported by the fact that all patients claimed to have been normal before narcotic use, that heroin reduced sexual performance and desire, and that a reversal to normal sexual function rapidly occurred during enforced withdrawal. Other observations by Ding (1972), and Scher (1967) support these findings. Berzins et al. (1971), and Mott (1972) have noted that drug-dependent subjects tend to have problems of sexual identity, and Hobi (1972) suggests that psychosexual immaturity is frequently seen in drug-dependent subjects.

scholarly journals Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of Bupropion as Treatment for Methadone-Emergent Sexual Dysfunction in Men

2018 ◽  
Vol 12 (5) ◽  
pp. 1705-1718 ◽  
Author(s):  
Anne Yee ◽  
Huai Seng Loh ◽  
Teng Aik Ong ◽  
Chong Guan Ng ◽  
Ahmad Hatim Sulaiman
Keyword(s):  
Sexual Dysfunction ◽  
Sexual Function ◽  
Erectile Function ◽  
Controlled Trial ◽  
Mean Difference ◽  
Plasma Testosterone ◽  
Double Blind ◽  
End Point ◽  
Parallel Group ◽  
Male Patients

Methadone is largely recognized as an effective treatment for opiate-dependent patients; however, it causes reduced brain dopaminergic action resulting in significant sexual dysfunction. Bupropion is a dopamine reuptake inhibitor which can potentially improve erectile function among male patients on methadone (MMT). This is a phase II, randomized, double-blind, parallel-group, placebo-controlled trial, involving 80 MMT male patients (73.4%) with mean age of 42.83 years ±9.68. These MMT male patients were randomly assigned into two groups to receive bupropion and placebo, respectively. The primary efficacy outcome measure was the difference between the two groups in end-point mean improvement scores using the measurement of Clinical Global Impression Scale adapted for Sexual Function (CGI-SF) at baseline (week 0) and at weeks 2, 4, and 6. Malay version of the sexual desire inventory-2 (SDI-2-BM) and Malay version of International Index of Erectile Function 15 (Mal-IIEF-15) domain scores were evaluated as secondary parameters. Improvement of the end-point mean from baseline were seen across the scores of SDI-2-BM (mean difference = 11.77 ± 2.90, 95% confidence interval (CI) [3.89, 19.54], p < .001) and Mal-IIEF-15 (mean difference = 8.37 ± 2.71, 95% CI [15.75, 0.99], p = .02), and the total plasma testosterone level (mean difference = 4.03, 95% CI [0.90, 7.15], p = .01). A categorical improvement of “much/very much improved” (CGI-SF score = 2) was reported by 58.3% ( n = 21/36) of bupropion SR-assigned versus 27.7% ( n = 10/36) placebo-assigned patient. Bupropion was well tolerated with no serious adverse events reported other than insomnia (17.7%). Six weeks of bupropion SR treatment reported significant improvement in key aspects of sexual function among male opiate-dependent patients on methadone maintenance treatment with emergent sexual dysfunction.

Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction

2005 ◽  
Vol 95 (4) ◽  
pp. 603-608 ◽  
Author(s):  
R. Jeroen A. van Moorselaar ◽  
Rudolf Hartung ◽  
Mark Emberton ◽  
Niels Harving ◽  
Haim Matzkin ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Once Daily ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Lower Urinary Tract Symptoms and Sexual Dysfunction in Male: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Guoda Song ◽  
Min Wang ◽  
Bingliang Chen ◽  
Gongwei Long ◽  
Hao Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Urinary Tract ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Meta Analysis ◽  
Assessment Tools ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Background: An association between lower urinary tract symptoms (LUTS) and risk of sexual dysfunction in male remains controversial in recent decades.Materials and Methods: PubMed and Web of Science were searched up to October 28, 2020, for articles reporting the prevalence of sexual dysfunction in men with LUTS. The main outcomes were results from sexual dysfunction assessments. Pooled odds ratio (OR) and weighted mean difference (WMD) with 95% confidence interval (CI) were calculated. The quality assessment of the included studies was performed by using The Newcastle-Ottawa Scale (NOS) or JBI Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI).Results: A total of 24 full-manuscript papers met the inclusion criteria. The pooled OR for 21 studies suggested that patients with severer LUTS had a higher risk of sexual dysfunction (OR = 3.31, 95% CI: 2.43 to 4.49, p &lt; 0.001, I2 = 90%). A significant decrease in scores of assessment tools for sexual dysfunction was observed in the patients with higher severity of LUTS compared with those patients with lower severity (WMD = −5.49, 95%CI: −7.25 to −3.27, P &lt; 0.001, I2 = 96%). Similar outcomes were also found in subgroup analyses. In a detailed analysis of specific sexual function domains, the severity of LUTS was associated with erectile dysfunction, intercourse satisfaction, and overall satisfaction, except for sexual desire.Conclusion: The study demonstrates an association between exposure of lower urinary tract symptoms and risk of sexual dysfunction in male. Assessment of sexual function is necessary for patients with lower urinary tract symptoms.Systematic Review Registration:http://www.crd.york.ac.uk/prospero, identifier: CRD42020208747.

scholarly journals Bupropion as a Treatment for Sexual Dysfunction Among Chronic Kidney Disease Patients

2019 ◽  
Author(s):  
Abolfazl Ghoreishi ◽  
Lila Dashtaki ◽  
Bahareh Hajisalimi
Keyword(s):  
Quality Of Life ◽  
Chronic Kidney Disease ◽  
Erectile Dysfunction ◽  
Sexual Dysfunction ◽  
Kidney Disease ◽  
Sexual Function ◽  
Total Quality ◽  
Significant Difference ◽  
Male Patients

Sexual dysfunction is a common complication among male patients with chronic kidney disease. Common disturbances include erectile dysfunction, decreased libido, and infertility. Sexual dysfunction is a multifactorial problem, and the treatment options are limited, it associated with lower quality of life scores in patients. Chronic kidney disease also has a critically impairing effect on the quality of life. To investigate the efficacy of bupropion on sexual dysfunction and quality of life in men with chronic kidney disease, a single-blind placebo-controlled trial was conducted. A total of 40 male patients with chronic kidney disease suffering from erectile dysfunction (Mean age 41/25±8/8) were randomly assigned to receive 10 weeks of treatment with either bupropion or placebo. Sexual function and quality of life were assessed by IIEF5 and WHOQOL-BREF questionnaires, respectively. Baseline demographic and clinical features were similar in both groups. The results showed a significant difference between the intervention and control groups in sexual function (P=0/005) and total quality of life (P=0/001); also the difference was significant in physical health (P=0/012), psychological health (P<0/001) and social relationship (P<0/001) domains. Our findings suggest that Bupropion is effective and safe for treating sexual dysfunction in men with chronic kidney disease and also could positively affect the quality of life among the patients. © 2019 Tehran University of Medical Sciences. All rights reserved. Acta Med Iran 2019;57(5):320-327.

Sign in / Sign up

Export Citation Format

Share Document